UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential.

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Vertex Pharmaceuticals ... is provided by the company.) Vertex is a global biotechnology company that invests in ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

Stifel raised the firm’s price target on Vertex (VERX) to $52 from $41 and keeps a Buy rating on the shares following what the firm calls ...

Vertex has initiated the RAINIER trial, a global Phase 3 clinical trial of ... while Raymond James resumed coverage with a Market Perform rating. RBC Capital Markets raised its price target ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, released new innovations, honored partners and ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential. The investment bank said it believes Vertex (VRTX) has “best in sector ...

There are 2,817 funds or institutions reporting positions in Vertex Pharmaceuticals ... Fintel has the most comprehensive coverage of global equities at prices individual investors can afford.

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, released new ...